Key facts
- The Financial Times, citing people familiar with the matter, reported J&J could announce an Ollin Biosciences deal for up to $3.4 billion as soon as Monday, November 16, 2026.
- The terms being discussed call for $2.2 billion in cash upfront and $1.2 billion in potential milestone payments, per the Financial Times.
- Ollin Biosciences raised $330 million in June 2026 to advance late-stage studies of its experimental eye drug OLN324.
- J&J bought biotech Firefly Bio for $1 billion in cash in 2026 and Intra-Cellular Therapies for $14.6 billion in 2025.
Johnson & Johnson is in talks to buy Texas-based biotech Ollin Biosciences for up to $3.4 billion and could announce a deal as soon as Monday, November 16, 2026, the Financial Times reported, citing people familiar with the matter. Reuters, which carried the report on November 15, said it could not immediately verify it.
Under the terms being discussed, J&J would pay Ollin's backers $2.2 billion in cash upfront and a further $1.2 billion in potential milestone payments, the newspaper reported.
Ollin raised $330 million in June 2026 to advance late-stage studies of its experimental eye disease drug OLN324, which targets diabetic macular edema and wet age-related macular degeneration, two leading causes of vision loss.
Neither Johnson & Johnson nor Ollin Biosciences immediately responded to Reuters' requests for comment outside business hours, Reuters said.
J&J acquired biotech Firefly Bio for $1 billion in cash in 2026 as it looked to expand its cancer drug pipeline. The company also bought drugmaker Intra-Cellular Therapies for $14.6 billion in 2025 to add neurological disorder treatments.
